Oncology and Hematology

Episodes 49-64 of 94

• 

  RestartResume

  Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

  RestartResume

  Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

  MinuteCE®

  Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  • 

    

    Ritu Salani, MD, MBA

  1.00 program credit

• 

  RestartResume

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  RestartResume

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  MinuteCE®

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• 

  RestartResume

  Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer   

  RestartResume

  Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer   

  MinuteCE®

  Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer   

  0.75 program credits

  • 

    

    Tanya Dorff, MD

  0.75 program credits

• 

  RestartResume

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  RestartResume

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  MinuteCE®

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  1.00 program credit

• 

  RestartResume

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  RestartResume

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  MinuteCE®

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  1.25 program credits

  • 

    

    Wenxin Xu, MD

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• 

  RestartResume

  Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences   

  RestartResume

  Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences   

  MinuteCE®

  Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences   

  0.75 program credits

  • 

    

    Rana McKay, MD

  0.75 program credits

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers

  1.25 credits 10 episodes

  • 

    

    Ignacio Duran, MD

  • 

    

    Wenxin Xu, MD

  • 

    

    Sandy Srinivas, MD

  1.25 credits 10 episodes

• 

  RestartResume

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  RestartResume

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  MinuteCE®

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  1.00 program credit

  • 

    

    Nicoletta Colombo, MD

  • 

    

    Ritu Salani, MD, MBA

  1.00 program credit

• 

  RestartResume

  Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer

  RestartResume

  Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer

  MinuteCE®

  Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer

  0.75 program credits

  • 

    

    Rana McKay, MD

  0.75 program credits

• 

  RestartResume

  Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer

  RestartResume

  Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer

  MinuteCE®

  Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer

  1.00 program credit

  • 

    

    Ritu Salani, MD, MBA

  • 

    

    Susana Campos, MD, MPH

  1.00 program credit

• 

  RestartResume

  Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer

  RestartResume

  Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer

  MinuteCE®

  Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  • 

    

    Wenxin Xu, MD

  1.25 program credits

• 

  RestartResume

  Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer

  RestartResume

  Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer

  MinuteCE®

  Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer

  1.00 program credit

  • 

    

    Ritu Salani, MD, MBA

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  RestartResume

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  RestartResume

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  MinuteCE®

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• 

  RestartResume

  Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment   

  RestartResume

  Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment   

  MinuteCE®

  Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment   

  0.75 program credits

  • 

    

    Tanya Dorff, MD

  • 

    

    Rana McKay, MD

  0.75 program credits

• 

  RestartResume

  Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

  RestartResume

  Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

  MinuteCE®

  Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

  1.00 program credit

  • 

    

    Ritu Salani, MD, MBA

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  RestartResume

  Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

  RestartResume

  Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

  MinuteCE®

  Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• Previous
• 1
• 2
• 3
• 4
• 5
• 6
• Next